Self-sealing device and method for delivery of a therapeutic agent through a pneumostoma

• US 8,021,320 B2
• Filed: 02/18/2009
• Issued: 09/20/2011
• Est. Priority Date: 02/19/2008
• Status: Expired due to Fees

• Current Assignee: Portaero, Inc
• Original Assignee: Portaero, Inc
• Inventors: Tanaka, Don, Wiesman, Joshua P., Plough, David C.
• Primary Examiner(s): Lucchesi; Nicholas D
• Assistant Examiner(s): Eisenberg; Rebecca E
• Application Number:
  US12/388,470
• Publication Number:
  US 20090209906A1
• Time in Patent Office: 944 Days
• Field of Search: 604/27, 604/47, 604/93.01, 604/264, 604506-507, 604 68- 72, 604/910, 128/200.24, 128/200.14, 128/200.17, 128/200.23, 128/207.14
• US Class Current: 604/27
• CPC Class Codes: A61B 2017/00809 Lung operations
• CPC Class Codes: A61K 9/007 Pulmonary tract; Aromatherapy
• CPC Class Codes: A61M 1/04 Artificial pneumothorax apparatus
• CPC Class Codes: A61M 11/00 Sprayers or atomisers specially adapted for therapeutic purposes in general B05B; aerosol containers B65D83/14
• CPC Class Codes: A61M 11/005 using ultrasonics spraying or atomising liquids using ultrasonic vibrations in general B05B17/06
• CPC Class Codes: A61M 11/042 electrical
• CPC Class Codes: A61M 13/00 Insufflators for therapeutic or disinfectant purposes , i.e. devices for blowing a gas, powder or vapour into the body hand-held units in which gas flow is produced by muscular energy at the moment of use B05B11/062
• CPC Class Codes: A61M 15/0085 using ultrasonics spraying or atomising liquids using ultrasonic vibrations in general B05B17/06
• CPC Class Codes: A61M 15/009 using medicine packages with incorporated spraying means, e.g. aerosol cans pocket atomiser of the injector type A61M11/08
• CPC Class Codes: A61M 15/02 with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles
• CPC Class Codes: A61M 16/0816 Joints or connectors
• CPC Class Codes: A61M 16/0833 T- or Y-type connectors, e.g. Y-piece
• CPC Class Codes: A61M 16/202 electrically actuated
• CPC Class Codes: A61M 2039/0252 for access to the lungs
• CPC Class Codes: A61M 2039/0276 for introducing or removing fluids into or out of the body
• CPC Class Codes: A61M 2202/0208 Oxygen
• CPC Class Codes: A61M 2202/025 Helium
• CPC Class Codes: A61M 2202/064 Powder
• CPC Class Codes: A61M 2205/075 Bulb type
• CPC Class Codes: A61M 2205/7518 bacterial
• CPC Class Codes: A61M 2205/7536 : allowing gas passage, but preventing liquid passage, e.g. liquophobic, hydrophobic, water-repellent membranes
• CPC Class Codes: A61M 25/02 : Holding devices, e.g. on the body
• CPC Class Codes: A61M 25/04 : in the body, e.g. expansible A61M25/10, A61M16/0488 take precedence
• CPC Class Codes: A61M 25/10 : Balloon catheters A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02; inflatable balloons for placing stents or stent-grafts A61F2/958 ; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00
• CPC Class Codes: A61M 27/00 : Drainage appliance for wounds or the like , i.e. wound drains, implanted drains negative pressure wound therapy devices A61M1/90; implements for holding wound open A61B17/02 ; middle ear drainage A61F11/202
• CPC Class Codes: A61M 39/02 : Access sites
• CPC Class Codes: A61M 39/0247 : Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body peritoneal dialysis catheters A61M1/285; tracheostomy devices A61M16/0465; measuring pressure within the body A61B5/03; colostomy devices A61F5/445; gastrotomy feeding tubes A61J15/0015; means for fixing a feeding tube outside of the body A61J15/0053

Abstract

A pneumostoma management system includes a pneumostoma management device for maintaining the patency of a pneumostoma and a drug delivery device for pneumostoma care. The drug delivery device may be used to introduce therapeutic agents into the pneumostoma for direct treatment of the pneumostoma, treatment of the lung by way of collateral ventilation, and/or treatment of non-lung tissues by diffusion into the bloodstream. The drug delivery device includes a therapeutic agent dispenser for supplying a therapeutic agent and a propellant at positive pressure, an outlet and a connector for correctly positioning the outlet relative to a pneumostoma management device. The drug delivery device includes a self-centering and self-sealing connector for engaging the pneumostoma management device.

Claims

1. A therapeutic agent delivery system for delivering a therapeutic agent through an artificial channel which passes through a chest wall, parietal membrane, visceral membrane and into a lung of a patient there being a seal between the visceral membrane and parietal membrane surrounding the artificial channel, the therapeutic agent delivery system comprising:

a pneumostoma management device which includes, a tube adapted to be placed through the artificial channel such that a distal end of the tube is positioned within the lung of the patient, a flange connected to a proximal end of the tube adapted to secure the pneumostoma management device to the chest wall of the patient and secure the tube within the artificial channel, and an aperture at the proximal end of the tube; and

a therapeutic agent delivery device including;

a container adapted to receive at least one dose of the therapeutic agent;

a self-sealing dispensing port that is adapted to communicate with the aperture of the pneumostoma management device; and

an actuator that can release the therapeutic agent;

whereby, with the pneumostoma management device secured in a pneumostoma and the self-sealing dispensing port coupled to the aperture of the pneumostoma management device, operation of the actuator releases the therapeutic agent through the self-sealing dispensing port via the aperture and tube of the pneumostoma management device through the chest wall and into the lung of the patient.

2. The system of claim 1, wherein the dispensing port is adapted to be self centering on the aperture of the pneumostoma management device.

3. The system of claim 1, wherein the dispensing port includes a conical flange adapted to engage the aperture of the pneumostoma management device.

4. The system of claim 1, wherein the dispensing port includes a self-sealing flange adapted to seal against a perimeter of the aperture of the pneumostoma management device.

5. The system of claim 1, wherein the dispensing port includes a compliant flange adapted to seal against a perimeter of the aperture of the pneumostoma management device.

6. The system of claim 1, wherein the dispensing port includes a deformable flange adapted to seal against a perimeter of the aperture of the pneumostoma management device.

7. The system of claim 1 wherein said container is adapted to receive a repository of one or more doses of the therapeutic agent.

8. The system of claim 1 wherein said container is adapted to receive an output of a nebulizer.

9. The system of claim 1 wherein said container is adapted to receive a canister of the therapeutic agent.

10. The system of claim 1 wherein said container is adapted to receive a repository having individually defined doses of the therapeutic agent.

11. The system of claim 1 including a repository having one or more doses of the therapeutic agent, which repository is selectably receivable by the container.

12. The system of claim 1 including a canister of the therapeutic agent, which canister is selectably receivable by the container.

13. A therapeutic agent delivery system for delivering a therapeutic agent through an artificial channel which passes through a chest wall, parietal membrane, visceral membrane and into a lung of a patient there being a seal between the visceral membrane and parietal membrane surrounding the artificial channel, the therapeutic agent delivery system comprising:

a pneumostoma management device which includes, a tube adapted to be placed through the artificial channel such that a distal end of the tube is positioned within the lung of the patient, a flange connected to a proximal end of the tube adapted to secure the pneumostoma management device to the chest wall of the patient and secure the tube within the artificial channel, and an aperture at the proximal end of the tube; and

a therapeutic agent delivery device including;

a container adapted to receive at least one dose of the therapeutic agent;

a self-centering and self-sealing dispensing port that is adapted to communicate with the aperture of the pneumostoma management device; and

an actuator that can release the therapeutic agent;

whereby, with the pneumostoma management device secured in a pneumostoma and the self-sealing dispensing port coupled to the aperture of the pneumostoma management device, operation of the actuator releases the therapeutic agent through the self-sealing dispensing port via the aperture and tube of the pneumostoma management device through the chest wall and into the lung of the patient.

14. The system of claim 13 wherein said dispensing port is conical.

15. The system of claim 13 wherein said dispensing port is compliant.

16. The system of claim 13 wherein said dispensing port is deformable.

17. The system of claim 13, wherein the dispensing port includes a conical flange adapted to engage the aperture of the pneumostoma management device.

18. The system of claim 13, wherein the dispensing port includes a self-sealing flange adapted to seal against a perimeter of the aperture of the pneumostoma management device.